Advances in Therapy

, Volume 31, Issue 9, pp 945–960

Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendations


  • Alfonso Berrocal
    • Department of OncologyHospital General Universitario
  • Luis Cabañas
    • Department of SurgeryHospital Ramón y Cajal
    • Department of Clinical OncologyHospital Universitario La Paz
  • Ricardo Fernández-de-Misa
    • Department of DermatologyHospital Nuestra Señora de Candelaria
  • Salvador Martín-Algarra
    • Department of OncologyClínica Universidad de Navarra
  • José Carlos Martínez-Cedres
    • Department of Radiotherapeutic OncologyHospital Nuestra Señora de Candelaria
  • Luis Ríos-Buceta
    • Department of DermatologyHospital Ramón y Cajal
  • José Luis Rodríguez-Peralto
    • Department of PathologyHospital Universitario 12 de Octubre

DOI: 10.1007/s12325-014-0148-2

Cite this article as:
Berrocal, A., Cabañas, L., Espinosa, E. et al. Adv Ther (2014) 31: 945. doi:10.1007/s12325-014-0148-2


The incidence of malignant melanoma is increasing worldwide. In Spain, its incidence is increasing faster than any other cancer type, with a 5-year survival rate of about 85%. The impact and characteristics of malignant melanoma in the Spanish population can be ascertained from the national melanoma registry of the Academia Española de Dermatología y Venereología. This review presents consensus group recommendations for the diagnosis, staging and treatment of malignant melanoma in Spain. Incidence and mortality are discussed, as well as evaluation of various prevention and treatment strategies. Prognostic factors, such as BRAF and C-KIT mutations, which are expected to become routine staging procedures over the next few years, are outlined, especially in relation to treatment options. The use of recently approved targeted agents such as ipilimumab, a cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibitor, and vemurafenib, a BRAF inhibitor, in metastatic disease are also discussed.


Diagnosis Malignant melanoma Oncology Prognosis Spain Standards Therapeutics

Supplementary material

12325_2014_148_MOESM1_ESM.pdf (267 kb)
Supplementary material 1 (PDF 266 kb)

Copyright information

© Springer Healthcare 2014